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http://dx.doi.org/10.1016/j.bgm.201Abstract Hypoxia is a condition of progressive depletion of cellular oxygen, encompassing a
variety of factors that have a sensitive interplay with the nucleus, DNA, and protein machinery.
The relevance of hypoxia with cancer biology has been increasingly observed in recent years;
however, currently there are major clinical obstacles in understanding the mechanism of tu-
mor progression and identifying the correct therapy. This review sheds light on the most recent
findings on hypoxia-induced factors that are involved in cancer progression, and relates them
to a network of signals that are co-involved in tumor growth. In this perspective, this review
elaborates on unanswered key questions with regard to regulation and modulation pathways
related to oxygen-deprived conditions during cancer development, including a brief view of
specific microRNA factors in hypoxia. The focus of this review is on the vast landscape of com-
ponents that are involved in tumor progression, including identification of potential targets
and pathways that can play a pivotal role in identifying clinical and diagnostic methods, with
hypoxia as a starting point. Defining novel and potential cell cycle factors is of significant
importance, particularly given the increasing emergence of personalized medicine.
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Hypoxia is a condition of progressive depletion of oxygen
caused by poor circulation to the cell or tissue. Oxygen
depletion principally creates a hostile condition to all kinds
of viable cells but this phenomenon regularly occurs when
the tumor volume exceeds a certain limit and thus serves as
an important contributor for the growth of cancer cells,
such as in cases of ovarian, breast, and hepatocellular
carcinomas.1e3 The process of cancer cell growth and its
progression includes several steps and events at the
biochemical level and depends on a vast number of cellular
and extracellular factors that are altered during the
transformation from a normal cellular condition to a cancer
cell. Early stages of cancer are often triggered and fueled
by hypoxia, regulatory imbalances in T-cell expression,
aberrant homeostasis, neoangiogenesis, endocrine, neuro-
crine, paracrine and autocrine triggering, and hormonal
imbalances.2,4e17 Hypoxia, in particular, leads to a series of
events taking place in the cell, altering its metabolic po-
tential and its growth-regulating mechanisms. Moreover, it
constitutes a major clinical obstacle in terms of tumor
progression and therapy, which is often diagnosed by bi-
opsies and serological profiling.
During serological and sample analysis, identifying the
expression patterns of cell factors are of pivotal importance,
as theyhavebeen for the past 70 years in diagnosticmedicine.
For this formidable task, biomarkers have been developed for
diagnostic purposes based on their involvement in cell cycles,
tumor progression, angiogenic responses, tissue remodeling,
and other pathophysiological processes.16,18e22 This partic-
ular approach of biomarking disease evolved after the Second
World War, when the first protein-expression patterns and
metabolites were studied in the context of heart disease and
neuronal cancer.23,24 Since then the vastmajority of diseases,
particularly hereditary, have been directly linked to a defi-
ciency inexpressionpatterns of pivotal proteins andenzymes,
with the most recognized example being the p53 tumor sup-
pressor.25,26 Diagnostic and prognostic importance of a cancer
biomarker concept is thus derived from sound and accurate
tissue analysis with a direct correlation to the patient’s clin-
ical parameters, and requires that the candidate biomarker
has a central presence in a cancer-associated biochemical
pathway.
This review focuses on the basic mechanisms of hypoxia-
related signaling pathways, which are central responses in
cell-survival reflexes. In light of the tumor biological
perspective of hypoxia, the key findings on the hypoxia-
inducible factor (HIF) family of proteins and their regula-
tory response to oxygen-deprived conditions are compre-
hensively summarized and elaborated, particularly with
regard to the microRNA (miRNA) network, which is an
emerging and increasingly studied field in tumor biology.
Also, the review describes how the knowledge about
hypoxia-related pathways can aid in identifying novel mo-
lecular biomarkers for clinical utility.
HIF proteins and oxygen-dependent regulation
In oxygen-deprived conditions, the most crucial event that
takes place in the cell is the induction of the HIF proteins.The HIF proteins regulate and effectuate the transcription
of numerous hypoxia-inducible genes during oxygen
depletion to increase cell-survival potential and constitute
a direct reference to tumor progression and aggressive-
ness.14,27 The HIF transcription factor 1 is a heterodimeric
protein of the basic helixeloopehelix PAS family of DNA-
binding proteins found in all metazoans, and uses its
heterodimeric structure to induce the expression of
hypoxia-responsive genes.28,29 HIF-1a and HIF-2a contain an
oxygen-dependent degradation domain (ODDD),30,31 making
their expression highly oxygen dependent. By contrast, the
HIF-1b unit, also referred to as aryl hydrocarbon receptor
nuclear translocator (ARNT), is constitutively expressed.32
Under normoxic conditions, the von HippeleLindau (VHL)
tumor suppressor binds to the ODDD and facilitates the
degradation of the HIF proteins by the 26S proteasome
system.33 The recognition of HIF-1a subunits by VHL is in
turn mediated by the activity of prolyl hydroxylase pro-
teins, which confer enzymatic hydroxylation of specific
prolyl residues within the HIF ODDD in an oxygen-
dependent manner.34,35 The survival responses induced by
HIF are shear responses to an oxygen- and nutrient-
deprived state of the cell, and the survival mechanism
triggers a cell cycle, which has features similar to tumori-
genesis (e.g., growth and proliferation).
During their survival-inducing function, the HIF proteins
seem to be utterly regulated by oxygen concentrations;
however, increasing evidence suggests that the accumu-
lating HIF proteins also exhibit relevant functions beyond
oxygen dependence.36 Saito and colleagues36 demonstrated
that HIF-2awas induced by the RELA protein, independently
of oxygen-dependent hydroxylation. The RELA protein is a
nuclear factor of the kB family, and constitutes an essential
function for endochondral ossification in cultured chon-
drocytes and embryonic skeletal growth inmice.37 Moreover,
the oxygen-independent HIF-1a/ARNT activity during nor-
moxic conditions in keratinocytes involves a yet uncharac-
terized oxygen-independent activity of the HIF in response
to normal physiological conditions of the epidermis.38 These
recent findings jointly suggest that HIF proteins are exerting
regular maintenance functions during normal physiological
conditions, but become crucial growth-inducing factors
during induced cell shocks, such as oxygen depletion. This
very aspect of carrying a strong survival-promoting poten-
tial, disguised by regular cell function, is a key aspect in
delineating putative biomarkers in the future, and can
directly aid in resolving deeper alternative functions of
seemingly regular genes in the cell machinery triggered by
extreme conditions, such as during hypoxic signaling.Hypoxic signaling and its implication in cancer
High expression of HIF-1a is pivotal in a variety of malig-
nancies, encompassing brain, lung, esophageal, stomach,
colorectal, prostate, uterine, and cervical carcinomas,
and the transcription of their downstream genes promotes
tumor growth and survival. In particular, it has been shown
that HIF-1a and HIF-2a are jointly expressed and corrob-
orate in the context of physiological and pathological
hypoxic conditions in rat insulin-secreting pancreatic b
cells39 or in the early stages of esophageal cancer.40 One
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cancer is supposed to be the loss of VHL function29,34;
however, in the following section, we present recent evi-
dence that HIF expression can also be dysregulated and
affected by tumor-associated signaling pathways. In
addition, we also comment on selected HIF-induced
transcriptional targets and HIF’s ambivalent contribution
to a cancer phenotype in terms of oncogenic and tumor-
suppressive settings.
HIF regulation in cancer
The molecular framework for altered HIF expression in
cancer was recently complemented by Pore et al.41 It was
demonstrated that the phosphoinositide 3-kinase (PI3K)
signaling pathwaydmediated by Akt1dinduces HIF-1a
expression. However, given the finding that inhibition of
mammalian target of rapamycin with rapamycin had no
significant effect on HIF-1a expression. Pore and et al41
claimed that the contribution of an additional and so far
unknown mediator downstream of AKT could control HIF
expression.41 Moreover, Brugarolas and co-workers42
showed that loss of TSC2, an important downstream
component of the PI3K axis, results in HIF-1a accumulation,
which in turn stimulates transcriptional activation of
vascular endothelial growth factor (VEGF), an important
downstream target of HIF-1a.
Complementarily to these findings, Cheng and co-
workers43 reported on an interesting observation with re-
gard to PI3K/AKT downstream effects. They demonstrated
that Egr-1 is involved in Epidermal growth factor (EGF)-
induced growth and invasiveness of ovarian cell lines. This
effect depends on the PI3K/AKT signaling pathways and
involves Egr-1 as the downstream component. Using the
small interfering RNA approach, Cheng and co-workers43
showed that Egr-1 expression downregulated E-cadherin
by inducing its transcriptional repressor Slug. Thus, the
potential participation of Egr-1/EGF in the PI3K/AKT
pathway, which is also highly relevant in a hypoxic condi-
tion and contributes to HIF-1a upregulation, might suggest
a potential link to the “missing pieces” in the puzzle of HIF-
1a regulation, as quoted by Pore et al.44 Given the fact that
the EGF axis is also highly relevant for tumorigenesis, a
possible interplay between EGF signaling and hypoxia-
related pathways can be hypothesized.
The cytokine 15-deoxy-delta12,14-prostaglandin J2
(PGJ2) is supposed to be a key endogenous negative
regulator of inflammation and angiogenesis,45 which can
be used by cells to resolve an inflammatory response.46e48
In this context, Zimmer et al showed that PGJ2 transla-
tionally inhibits HIF-2a by recruiting iron regulatory
protein-1 (IRP1), which is involved in regulating the
transcriptome network and is dependent on an iron-
responsive element within the 50-untranslated region of
the HIF-2a message.49,50 Interestingly, this was supposed
to be the first report showing that anti-inflammatory and
putative antineoplastic effects of PGJ2 may be mediated
through inhibition of HIF-2a within the tumor epithelial
cells and/or mesenchymal cells of the tumor microenvi-
ronment. Given that HIF-2a is expressed during hypoxia
and tumor-promoting inflammatory cytokines aretriggered,51 it is feasible that the IRP1 might be down-
regulated by an unknown oncogenic factor, which in turn
induces HIF-2a to produce protumorigenic effects.
Conspicuously, the study by Fang and co-workers51 is of
particular interest, as it shows a connection between HIF-
2a, inflammation, and cancer. Thus, a cellular response
that should normally resolve an inflammatory condition
might be “misapplied” by cancer cells to increase angio-
genic capacity, thus promoting tumorigenesis through
iterative inflammation.
Recent findings suggest that estrogen receptor (ER)
signaling can directly interfere with HIF transcriptional
activity in a tumor biological context. It was demonstrated
that ER-b contributes to ARNT downregulation.52 Thus, a
potential tumor-suppressing function of the estrogen-b re-
ceptor takes place by attenuating the induction of VEGF, an
important HIF-1a downstream target (Fig. 1). By decreasing
the formation of functionally active HIF-1a/ARNT com-
plexes and depleting VEGF levels, ER-b might impair the
tumor’s angiogenic response,52 which makes estrogen a
potential target of repression by hypoxia-mediated tumor-
igenic responses.
HIF’s transcriptional targets and their ambivalent
roles
In macrophages experiencing hypoxia, HIF-1a and HIF-2a
regulate transcription of a variety of cytokines and chemo-
kines, including vasodilating adrenomedullin, VEGF A, inter-
leukin-1b (IL-1b) and IL-8, CXCR4, and angiopoietin-2.39,51 Of
themany potent tumor-promoting cytokines, adrenomedullin
is a protein that facilitates angiogenesis through paracrine
and autocrine pathways and it was recently found to be
involved in the progression of melanoma.53
Wang and et al54 recently suggested that HIF-1a tran-
scriptional targets can have a direct impact on oncogenic
Epidermal growth factor receptor (EGFR) signaling. It was
demonstrated that calveolin-1 expression is induced by
HIF-1a, which accentuates the formation of specialized
raft lipid microdomains (caveolae). This in turn promotes
EGFR dimerization followed by its ligand-independent
activation.54 These findings are of particular interest as
they underscore a further mechanism by which HIF tran-
scriptional targets contribute to the oncogenic potential
of tumor cells. It is shown that tumor cells can bypass the
dependence on EGF ligand and adapt downstream
signaling under hypoxic conditions.
The aforementioned studies implied a rather tumor-
promoting role of HIF; however, there are contradicting
findings on the function of HIF proteins. Wild-type HIF-1a
was recently found to act as a tumor suppressor rather
than an oncogene in kidney cancers harboring 14q de-
letions.55 The findings by Shen et al55 suggest that HIF-1a
requires pivotal cofactors expressed at the 14q locus to
carry out its tumor-promoting activity during hypoxia, but
these are largely unknown. The requirement of these un-
known factors may also be partially linked to a recent
study on a mouse model for inflammatory kidney disease
by Kobayashi et al.56 Kobayashi et al56 showed that HIF-1a
suppresses inflammation and fibrogenesis by directly or
indirectly downregulating CC chemokine receptors in
Figure 1 Hypoxia-induced oncogenic pathways. The complex network of HIF-inducible factors is depicted in relation to the most
defining cellular processes that sustain oncogenesis, angiogenesis, proliferation, differentiation, inflammation, remodeling, and
growth. Red arrows indicate stimulation, whereas blue arrows indicate suppression. The same color pattern is arranged for the names
of cellular and nuclear factors. HIF-1, HIF-2, and HIF-3 denote HIF-1a, HIF-2a, and HIF-3a4, respectively. HIFZ hypoxia-inducible
factor; ARNTZ aryl hydrocarbon receptor nuclear translocator; ADMZ adrenomedullin; ERZ estrogen receptor; EGFRZ epidermal
growth factor receptor; ERKZ extracellular signal-regulated kinase; GPDL1Z glycerol-3-phosphate dehydrogenase 1-like protein;
IRPZ iron-regulatory protein; MAPKZ mitogen-activated protein kinase; mRNAZ messenger RNA; mTORZ mammalian target of
rapamycin; PTENZ phosphatase and tensin homolog; VEGF-RZ vascular endothelial growth factor receptor.
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reaction that can mediate cancer,57 the role of HIF-1a in
suppressing inflammation shows that there are presently
missing pieces in our understanding of hypoxia-induced
cancer network. The question on which factors or
context is needed that make HIF proteins act in a pro-
versus antitumorigenic manner may thus be a crucial
avenue to be investigated in future cellular studies and
may serve to complete our picture on how hypoxia can
“fuel” cancer.HIF-3a: A suppressor of HIF-associated
tumorigenesis?
HIF-1a and HIF-2a subunits have two transactivation do-
mains, an N-terminal transactivation domain (NAD) and a C-
terminal transactivation domain, which are involved in DNA
binding and transcriptional regulation.58,59 The HIF-3a
subunit differs from HIF-1 and HIF-2a and contains only a
NAD.60 So far, only a little is known about the expression
pattern and function of HIF-3a in human cells. A recent
investigation verified HIF-3a expression in the human kid-
ney and showed that this subunit suppresses HIF-mediated
gene expression.60 In this context, the authors hypothe-
sized a competition of HIF-3a and HIF-1a or HIF-2a for the
recruitment of ARNT factor. Complementarily, HIF-3a4, an
alternatively spliced variant of human HIF-3a, was shown to
form a complex with HIF-1a and HIF-2a, which has an
abortive role on the transactivation of hypoxia-responseelements in terms of negative regulating factor. More-
over, HIF-3a4 was shown to be dramatically downregulated
in primary renal carcinomas and confers a growth-
suppressive effect in VHL-null renal carcinoma xenografts
by decreasing HIF-2a-mediated gene expression and has
been suggested as a putative tumor suppressor.61,62 In
accordance with these findings, Torii and co-workers63
investigated the inhibitory PAS (Per/ARNT/Sim) domain
protein (IPAS), a further alternatively spliced variant of HIF-
3a, and described it in the context of a dominant negative
feedback inhibitor of HIF-dependent hypoxic response.
Interestingly, besides the known contribution of HIF-3a
splice variants to transcriptional repression, the authors
sophisticatedly demonstrated that IPAS critically interferes
with the interaction of Bcl/xL with Bax and induces
apoptosis in prostate carcinoma cells.63Hypoxia-induced signaling and the
identification of novel biomarkers
Detailed knowledge about hypoxia-associated signaling
pathways is useful to identify novel cancer biomarkers. In a
recent investigation by Tong and co-workers,64 HIF-1a
expression in the bone marrow was determined by immu-
nohistochemical analysis. The group predicted poor survival
and recurrence of myelodysplastic syndrome, revealing a
central clinical role for the HIF axis in pathology. In their
study, Tong and co-workers64 analyzed samples from pa-
tients with surgically treated intracranial meningiomas for
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study, the expression of HIF proteins and VEGF was found to
be a good predictor of tumor recurrence65 as well as a good
biomarker for early stages of esophageal cancer along with
the BCL-2 expression, which is highly oxygen dependent.40
Thus, based on the aforementioned studies, not only HIF
but also the downstream components in this axis might be
promising biomarkers in tumor pathology.
One of these downstream components is related to the
expression of the voltage-dependent anion channel 1
(VDAC1-DC), which is interestingly expressed in patients
with lung cancer.66
In addition, for other neurological malignancies such as
glioblastoma, hypoxia has been described as a challenging
clinical obstacle. Glioblastoma has a high metabolic de-
mand, leading to relative tissue hypoxia and necrosis,
which confers therapy resistance.67 Monitoring tissue hyp-
oxia in those patients and estimating therapy response are
of significant clinical interest. Therefore, Tateishi and co-
workers68 recently described a method of noninvasive ox-
ygen measurement in the brain by hypoxic positron emis-
sion tomography imaging. In this context, they used 62Cu-
ATSM as a radiotracer. Uptake of this tracer into the cells is
dependent on cellular oxygen concentration. 62Cu-ATSM
uptake was shown to predict HIF-1 positivity in the tumor
tissue, providing an auxiliary diagnostic tool to evaluate
tumor hypoxia in patients with glioblastoma. Not only single
components of hypoxia-induced signaling pathways, but
also global signatures of hypoxia-inducible genes were
shown to be predictive for prognosis and therapy effi-
ciency69,70 in cancer patients.Conclusion
The mechanism of hypoxia depends on a variety of cellular
factors, with HIF proteins playing a central role. Recent
findings enlarge our picture of HIF in cancer and imply a
complex interplay with cytokine networks and important
signaling pathways including EGFR, PI3K, or ER axes (Fig. 1).
In this context, the cancer cell’s adaption to a hypoxic
microenvironment seems to be an essential “fueling”
mechanism for tumor progression. Upon metabolic adap-
tion to an oxygen-deprived condition, cancer cells become
more aggressive or even completely therapy resistant.
However, evidence is accumulating that hypoxic signaling
does not exclusively contribute to oncogenic effects and
could also be associated with tumor-suppressive and pro-
apoptotic cascades.
Presently, understanding and interpretation of hypoxic-
response biology is highly fragmented. There are a lot of
“missing parts” in the molecular puzzle of HIF and its
downstream effects, and further efforts will have to be
carried out to identify factors that are necessary for dis-
tinguishing oncogenic from tumor-suppressive and proapo-
ptotic responses of hypoxia-induced signaling. In addition,
the miRNA network, which is briefly discussed here, seems
to comprise fundamental mediators of hypoxic response
and hypoxia-related tumorigenicity. Considering this
involvement of miRNA networks, our picture of hypoxic-
response biology is complicated even further; however,specific and sensitive assays for miRNA detection as well as
molecular tools for miRNA-expression modulation are
available.
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